Sure.
All they need to do is prove they have something that does what they have been saying it can do and is financially viable in a real world setting and investors and partners will be beating down their door and fighting for a piece of the pie. Once proven, they won't be worrying about revenues or struggling to manage all this on their own
In a computer world it might be that easy.
In the real world, it takes time and lots of money and so easy to write something like this, isn't it. "all they need to prove is that they have something"
Well, why do you think it has taken as long as it has? it takes time and money, time and money, simple concepts. The M.D. Anderson report is based on time and money spent to get to the point of reading that Manhattan Scientifics’ Unparalleled Cancer Measurement Technology Featured in MD Anderson Presentation
Institutional investors will invest when they see something worth investing in.
There are almost never any big institutional investors or large mutual fund managers that invest in OTC stocks.
It will take more time and money to reach the point of II cozying up to mhtx and yes, more dilution. This is the fact of life with OTC based penny stocks.
As I wrote earlier, dilution for the right reason is fine with me. More instruments and FDA work is the right reason.
GLTA
News 
Market Data 
Discover 
AI
